Wilbs, JonasJonasWilbsKong, Xu-DongXu-DongKongMiddendorp, Simon JSimon JMiddendorpPrince, RajaRajaPrinceCooke, AlidaAlidaCookeDemarest, Caitlin TCaitlin TDemarestAbd El Hafez, Mai Moustafa AhmedMai Moustafa AhmedAbd El HafezRoberts, KalliopeKalliopeRobertsUmei, NaoNaoUmeiGonschorek, PatrickPatrickGonschorekLamers, ChristinaChristinaLamersDeyle, KaycieKaycieDeyleRieben, RobertRobertRieben0000-0003-4179-8891Cook, Keith EKeith ECookAngelillo, AnneAnneAngelilloHeinis, ChristianChristianHeinis2024-09-202024-09-202020-08-04https://boris-portal.unibe.ch/handle/20.500.12422/44954Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or inhibition in animals reduced thrombosis without causing abnormal bleeding. Herein, we have engineered a macrocyclic peptide inhibitor of activated FXII (FXIIa) with sub-nanomolar activity (Ki = 370 ± 40 pM) and a high stability (t1/2 > 5 days in plasma), allowing for the preclinical evaluation of a first synthetic FXIIa inhibitor. This 1899 Da molecule, termed FXII900, efficiently blocks FXIIa in mice, rabbits, and pigs. We found that it reduces ferric-chloride-induced experimental thrombosis in mice and suppresses blood coagulation in an extracorporeal membrane oxygenation (ECMO) setting in rabbits, all without increasing the bleeding risk. This shows that FXIIa activity is controllable in vivo with a synthetic inhibitor, and that the inhibitor FXII900 is a promising candidate for safe thromboprotection in acute medical conditions.en600 - Technology::610 - Medicine & healtharticle10.7892/boris.1457643275363610.1038/s41467-020-17648-w